Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04040088 · ClinicalTrials.gov registry record · Early Phase 1
An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors
A Early Phase 1 study of Neuroblastoma and Ganglioneuroblastoma, sponsored by Mayo Clinic.
- Active
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04040088 is a Early Phase 1 study of Neuroblastoma and Ganglioneuroblastoma that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 20 participants, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04040088, a Early Phase 1 study of Neuroblastoma and Ganglioneuroblastoma, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial studies how well an investigational scan called 68Ga-DOTATATE PET/CT works in diagnosing pediatric patients with neuroendocrine tumors that have spread to other places in the body (metastatic). A neuroendocrine tumor is an abnormal growth of neuroendocrine cells, which are cells resembling nerve cells and hormone-producing cells. 68Ga-DOTATATE is a radioactive substance called a radiotracer that when used with PET/CT scans, may work better than standard of care MIBG scans in diagnosing pediatric metastatic neuroendocrine tumors and targeting them with radiation therapy.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Positron Emission Tomography
- DRUG Gallium Ga 68-DOTATATE
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-09-23 |
| Est. Completion | 2026-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04040088
The ClinicalTrials.gov registry entry for NCT04040088 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (92% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Neuroblastoma appearing as the primary indexed condition, and to 3 interventions - of which Computed Tomography is the first listed.
NCT04040088 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT04040088 about?
NCT04040088 is a clinical study titled "An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors". This trial studies how well an investigational scan called 68Ga-DOTATATE PET/CT works in diagnosing pediatric patients with neuroendocrine tumors that have spread to other places in the body (metastatic). A neuroendocrine tumor is an abnormal growth of neuroendocrine cells, which are cells resemblin...
What is the current status of trial NCT04040088?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2019-09-23. Estimated completion is 2026-07.
What conditions does trial NCT04040088 study?
This clinical trial studies the following conditions: Neuroblastoma, Ganglioneuroblastoma, Ganglioneuroma.
What interventions are being tested in trial NCT04040088?
The interventions under investigation include: Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), Gallium Ga 68-DOTATATE (DRUG).
Who is sponsoring clinical trial NCT04040088?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04040088 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of N9 Chemotherapy in Children With Neuroblastoma
ACTIVE NOT RECRUITING · Early Phase 1
-
18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma
ACTIVE NOT RECRUITING · Early Phase 1
-
Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma
COMPLETED · Early Phase 1
-
MCT for the Harvard/UCSF ROBIN Center
RECRUITING · NA
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.